Moderna COVID-19 Vaccine (Spikevax)

Moderna, Inc. is an American biotechnology company based in Cambridge, Massachusetts, that rose to global prominence for its development of an mRNA-based COVID-19 vaccine. Founded in 2010, the company specializes in messenger RNA (mRNA) drug discovery, drug development, and vaccine technologies.

While headquartered in the United States, Moderna's manufacturing footprint is truly global. The company utilizes a network of its own facilities as well as partnerships with contract manufacturing organizations (CMOs) such as Lonza in Switzerland and various partners in Spain, France, and South Korea to ensure international supply. This distributed manufacturing model allows for rapid production and distribution of their therapeutics.

Moderna remains a publicly traded independent company listed on the NASDAQ. It is not owned by a larger pharmaceutical conglomerate, which distinguishes it from many other biotech firms that are eventually acquired. The company continues to invest heavily in its mRNA platform to develop treatments for infectious diseases, immuno-oncology, and rare diseases.